[
  {
    "ts": null,
    "headline": "Kenvue (KVUE): Exploring Valuation After Recent Share Price Weakness",
    "summary": "Kenvue (KVUE) shares have shown a mixed performance in recent weeks, with small daily moves resulting in a gradual decline over the past month. Investors are weighing the current momentum and considering how longer-term trends might shape the stock’s outlook. See our latest analysis for Kenvue. After a solid start to the year, Kenvue’s share price has lost steam with a 30-day return of -12.89% and a year-to-date share price return of -23.78%. Momentum has clearly faded, which reinforces that...",
    "url": "https://finnhub.io/api/news?id=bc2baf3b09e5d816f439233fdc07106355a17447dc8eb676671fe7fd36f788b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759957941,
      "headline": "Kenvue (KVUE): Exploring Valuation After Recent Share Price Weakness",
      "id": 137028530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Kenvue (KVUE) shares have shown a mixed performance in recent weeks, with small daily moves resulting in a gradual decline over the past month. Investors are weighing the current momentum and considering how longer-term trends might shape the stock’s outlook. See our latest analysis for Kenvue. After a solid start to the year, Kenvue’s share price has lost steam with a 30-day return of -12.89% and a year-to-date share price return of -23.78%. Momentum has clearly faded, which reinforces that...",
      "url": "https://finnhub.io/api/news?id=bc2baf3b09e5d816f439233fdc07106355a17447dc8eb676671fe7fd36f788b6"
    }
  },
  {
    "ts": null,
    "headline": "How the Narrative Around Kenvue Is Shifting Amid Legal and Regulatory Headwinds",
    "summary": "Kenvue's fair value estimate has recently been adjusted from $22.13 to $21.70. This reflects analysts' tempered expectations in light of evolving industry dynamics. This shift comes as experts weigh ongoing litigation, regulatory headlines, and muted top-line growth against Kenvue's core strengths and future portfolio strategies. Stay tuned to learn how you can continue monitoring the evolving consensus and keep ahead of further narrative shifts around Kenvue stock. What Wall Street Has Been...",
    "url": "https://finnhub.io/api/news?id=1c08dc8b57f9904472b4785b4bdf6d6252ae6b4b1dbb44899f7b4d0f4ced597a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759950639,
      "headline": "How the Narrative Around Kenvue Is Shifting Amid Legal and Regulatory Headwinds",
      "id": 137028531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Kenvue's fair value estimate has recently been adjusted from $22.13 to $21.70. This reflects analysts' tempered expectations in light of evolving industry dynamics. This shift comes as experts weigh ongoing litigation, regulatory headlines, and muted top-line growth against Kenvue's core strengths and future portfolio strategies. Stay tuned to learn how you can continue monitoring the evolving consensus and keep ahead of further narrative shifts around Kenvue stock. What Wall Street Has Been...",
      "url": "https://finnhub.io/api/news?id=1c08dc8b57f9904472b4785b4bdf6d6252ae6b4b1dbb44899f7b4d0f4ced597a"
    }
  },
  {
    "ts": null,
    "headline": "Does Tylenol Scrutiny Challenge Kenvue's (KVUE) Resilience in Navigating Public Perception and Regulatory Pressure?",
    "summary": "Following comments from former President Donald Trump urging pregnant women to avoid Tylenol unless necessary, Kenvue has faced heightened political scrutiny amid public debate about the safety of its flagship product. Despite the controversy, the World Health Organization maintains there is no conclusive evidence linking Tylenol use during pregnancy to neurodevelopmental disorders, highlighting the role of scientific guidance amidst market uncertainty. We will examine how increased...",
    "url": "https://finnhub.io/api/news?id=0bd4874cae1d512817a8d9868ebd59d505f8ce40efb4baf948f073a9a2662e6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759929453,
      "headline": "Does Tylenol Scrutiny Challenge Kenvue's (KVUE) Resilience in Navigating Public Perception and Regulatory Pressure?",
      "id": 137011168,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Following comments from former President Donald Trump urging pregnant women to avoid Tylenol unless necessary, Kenvue has faced heightened political scrutiny amid public debate about the safety of its flagship product. Despite the controversy, the World Health Organization maintains there is no conclusive evidence linking Tylenol use during pregnancy to neurodevelopmental disorders, highlighting the role of scientific guidance amidst market uncertainty. We will examine how increased...",
      "url": "https://finnhub.io/api/news?id=0bd4874cae1d512817a8d9868ebd59d505f8ce40efb4baf948f073a9a2662e6a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Johnson & Johnson (NYSE:JNJ) is one of America’s most recognizable healthcare companies, with operations that now center on pharmaceuticals and medical devices. After spinning off its consumer health unit, which included familiar names like Tylenol, Neutrogena, and Listerine, into […]",
    "url": "https://finnhub.io/api/news?id=ac153d28000ac47d8816c6e3b5b48fe2a2d6a54e5665dda2fc8ca0c7019546ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759902222,
      "headline": "Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks",
      "id": 137007973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Johnson & Johnson (NYSE:JNJ) is one of America’s most recognizable healthcare companies, with operations that now center on pharmaceuticals and medical devices. After spinning off its consumer health unit, which included familiar names like Tylenol, Neutrogena, and Listerine, into […]",
      "url": "https://finnhub.io/api/news?id=ac153d28000ac47d8816c6e3b5b48fe2a2d6a54e5665dda2fc8ca0c7019546ab"
    }
  }
]